AUPH Class Action: Learn About the Aurinia Pharmaceuticals Lawsuit

Levi & Korsinsky, LLP announces that an AUPH class action lawsuit has been filed on behalf of investors who purchased Aurinia Pharmaceuticals Inc. (AUPH) securities between May 7, 2021, and February 25, 2022. For more on the AUPH Lawsuit please contact us today.  

According to the Aurinia Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia’s 2022 sales outlook for the Company’s only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE AUPH CLASS ACTION LAWSUIT, CLICK HERE 

If you suffered a loss in Aurinia Pharmaceuticals you have until June 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. 

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

You may also like...